About Allarity Therapeutics, Inc. - Common stock (ALLR)
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies that target specific molecular drivers of tumors. The company utilizes its proprietary drug development platform to identify and enhance the effectiveness of treatments tailored for individual patient profiles, particularly in cases of advanced or difficult-to-treat cancers. By leveraging advanced technologies, Allarity aims to improve patient outcomes through personalized medicine approaches that align therapies with the unique characteristics of a patient's tumor, ultimately striving to bring more effective options to the oncology landscape. Read More
- Stenoparib continues to demonstrate clinical benefit in heavily pre-treated ovarian cancer, with two patients remaining on treatment for more than 19 months- Initiated utilization of share repurchase program- Cash and restricted cash balance of approximately $27 million at end of Q1 2025, reinforcing financial stability
U.S. stock futures were swinging between gains and losses on Tuesday after a mixed session on Monday. Futures of major benchmark indices were mixed in premarket trading. President Donald Trump‘s “Liberation Day”, the term he’s used for April 2nd, the day of incoming reciprocal tariffs, preceded a drop in stock prices.
Speculation over an impending reverse merger, a Phase 2 trial announcement, comments about upcoming cancer screening tests, a Medicare business deal, and an obesity drug partnership sparked buzz among Stocktwits users for the week ended March 7, 2025.
Boston (February 26, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific patient selection technology—the Drug Response Predictor (DRP®)—today announced that the securities class action lawsuit in the United States District Court for the Southern District of New York referenced in the Company’s Form 10-Q filing on November 11, 2024, has been dismissed in whole against all defendants.
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Allarity Therapeutics, Inc. (“Allarity” or “the Company”) (NASDAQ: ALLR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR) and reminds investors of the November 12, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Rosen Law Firm, a global investor rights law firm, reminds purchasers and acquirers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the “Class Period”), of the important November 12, 2024 lead plaintiff deadline. Allarity is a clinical-stage biopharmaceutical company.
